Mycoses

Latest News

Echinocandins Recommended as Optimal First-Line Treatment for Invasive Candidiasis

By

Maria Arini Lopez, PT, DPT, CSCS, CMTPT

Researchers evaluated the safety and efficacy of several antifungal agents for the treatment of invasive candidiasis infection.

Chronic Pulmonary Aspergillosis Recurrence With 6 vs 12 Months of Itraconazole

By

Maria Arini Lopez, PT, DPT, CSCS, CMTPT

Researchers conducted a study that assessed the rate of chronic pulmonary aspergillosis recurrence among patients who received oral itraconazole for 6 vs 12 months.

Fluconazole vs Other Antifungals for Esophageal Candidiasis in Patients With HIV

By

Jessica Nye, PhD

In this meta-analysis, researchers assessed the safety and efficacy of fluconazole compared with alternative antifungal agents for the treatment of esophageal candidiasis.

Study Shows Ibrexafungerp Prevents Recurrent Vulvovaginal Candidiasis

By

Brian Park, PharmD

The phase 3 CANDLE study compared the efficacy and safety of ibrexafungerp to placebo in 260 female patients 12 years of age and older with rVVC.

Attributable vs Crude Mortality in Candida Bloodstream Infections

By

Jessica Nye, PhD

Researchers conducted a study that assessed the rate of 90-day all-cause crude mortality vs attributable mortality among patients with candida bloodstream infections.

Risk for Triazole-Resistant Aspergillosis From Composting, Other Gardening Activities

By

Jessica Nye, PhD

Researchers conducted a study to determine whether gardening activities are associated with an increased risk for exposure to triazole-resistant Asperigillus fumigatus fungal spores.

Does Quinine Potentiate Antimicrobial Blue Light Therapy in Patients With Cutaneous Mold Infection?

By

Estie Mermelstein, MSN, FNP-BC

Investigators conducted a study to determine the effects of quinine hydrochloride in combination with antimicrobial blue light therapy in patients with cutaneous mold infection.

Early De-escalation to Fluconazole for Fluconazole-Susceptible Candidemia

By

Rita Aghjayan

Investigators conducted a study to determine outcomes following early de-escalation to fluconazole following echinocandin empirical treatment in patients with fluconazole-susceptible candidemia.

Global Epidemiology of Fungal Keratitis and Its Outcomes

By

Bradley van Paridon

Investigators analyzed data collected over more than 70 years to estimate the annual global incidence of this severe corneal infection.

Ibrexafungerp Gets Priority Review for Vulvovaginal Candidiasis

By

Brian Park, PharmD

The FDA has accepted for filing and granted Priority Review to the NDA for ibrexafungerp (SCY-078; Scynexis) for the treatment of vulvovaginal candidiasis.

Antifungal Prophylaxis in Hematological Disease or Hematopoietic Stem Cell Transplantation

By

Bradley van Paridon

Investigators summarized the evidence on the efficacy and adverse effects of antifungal agents in patients with hematological disease or undergoing hematopoietic stem cell transplantation.

Increased Risk of Mycobacterial Infection With Immune Checkpoint Inhibitors

By

Christina Bennett, MS

Using FAERS, study researchers identified reported cases of tuberculosis and atypical mycobacterial infection in patients who received ICIs.

Invasive Aspergillosis Superinfection Possible in Symptomatic COVID-19

By

Zahra Masoud

Critically ill patients hospitalized with COVID-19 — particularly those who develop ARDS — may also experience an opportunistic aspergillosis superinfection.

Terbinafine, Fluconazole, and Itraconazole for Dermatophyte Toenail Onychomycosis

By

Brandon May

A novel study used network meta-analysis to compare pulse and continuous systemic therapies for toenail onychomycosis.

Generic Version of Antifungal Drug Mycamine Now Available

By

Brian Park, PharmD

Fresenius Kabi announced the launch of Micafungin for Injection, a generic version of Mycamine (micafungin for injection; Astellas Pharma).

Value of Persistently Negative (1,3)-β-D-Glucan in Adults With Candidemia

By

Bradley van Paridon

Adults with candidemia and persistently negative (1,3)-β-D-glucan tests present with a better prognosis than comparative groups.

Inhaled Itraconazole Fast-Tracked for Allergic Bronchopulmonary Aspergillosis in Asthma

By

Brian Park, PharmD

The FDA has granted Fast Track designation to PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma.

Investigations of Pan-Resistant C auris Cases After Antifungal Treatment

By

Bradley van Paridon

The Centers for Disease Control and Prevention (CDC) summarized investigations into 3 cases of pan-resistant Candida auris infections in New York.

Injectable Micafungin Approved for Invasive Candidiasis in Younger Patients

By

Brian Park, PharmD

The FDA has approved the sNDA for Mycamine for the treatment of candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients aged <4 months.

Oral Ibrexafungerp Effective in Vulvovaginal Candidiasis Trial

By

Brian Park, PharmD

Scynexis announced positive topline results from the phase 3 VANISH 303 trial of ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) in women.